NASDAQ:AMEDAmedisys Stock Price, Forecast & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AMED stock has increased by 12.7% and is now trading at $192.05. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings results on Wednesday, May, 6th. The health services provider reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.97 by $0.08. The health services provider earned $491.70 million during the quarter, compared to the consensus estimate of $507.45 million. Amedisys had a net margin of 6.43% and a return on equity of 23.09%. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.11 earnings per share. View Amedisys' earnings history.

14 equities research analysts have issued 12-month price targets for Amedisys' stock. Their forecasts range from $125.00 to $240.00. On average, they expect Amedisys' share price to reach $191.07 in the next year. This suggests that the stock has a possible downside of 0.5%. View analysts' price targets for Amedisys.

News articles about AMED stock have trended somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a daily sentiment score of 0.6 on InfoTrie's scale. They also assigned news stories about the health services provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutAmedisys.

Amedisys saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,110,000 shares, a drop of 8.3% from the April 30th total of 1,210,000 shares. Based on an average daily volume of 314,000 shares, the short-interest ratio is presently 3.5 days. Approximately 3.5% of the company's shares are short sold. View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.85%), Wellington Management Group LLP (4.86%), State Street Corp (3.14%), William Blair Investment Management LLC (3.00%), JPMorgan Chase & Co. (2.72%) and Riverbridge Partners LLC (2.05%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Eaton Vance Management, William Blair Investment Management LLC, Principal Financial Group Inc., Quantitative Investment Management LLC, Rothschild & Co. Asset Management US Inc., Loomis Sayles & Co. L P, and Morgan Stanley. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz. View insider buying and selling activity for Amedisys.

AMED stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., AXA, Federated Hermes Inc., APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Two Sigma Advisers LP, and Invesco Ltd.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps. View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $192.05.

Amedisys has a market capitalization of $6.22 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]